Asahi Kasei Pharma starts Phase III study of CIPN prevention therapy
Previous Phase I and II studies suggest efficacy and patient tolerability of ART-123 for CIPN by suppressing the activation of…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.